The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases [0.03%]
肝外转移性肝细胞癌的局部区域治疗地位
Beom Kyung Kim
Beom Kyung Kim
Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma [0.03%]
肝细胞癌多结节型BCLC-A期患者一线治疗中肝脏切除术角色的探索研究
Joo Hyun Oh,Dong Hyun Sinn
Joo Hyun Oh
Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study [0.03%]
2008年至2022年韩国肝细胞癌治疗模式的演变趋势：一项全国人群为基础的研究
Ji Won Han,Won Sohn,Gwang Hyeon Choi et al.
Ji Won Han et al.
Backgrounds/aims: The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database from...
Valentina Zanuso,Giulia Tesini,Elena Valenzi et al.
Valentina Zanuso et al.
Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone of advanced CCA treatme...
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma [0.03%]
乙型肝炎病毒相关肝细胞癌的疾病修饰因子和新标记物
Lung-Yi Mak
Lung-Yi Mak
Chronic hepatitis B (CHB) infection is responsible for 40% of the global burden of hepatocellular carcinoma (HCC) with a high case fatality rate. The risk of HCC differs among CHB subjects owing to differences in host and viral factors. Mod...
Recent update of proton beam therapy for hepatocellular carcinoma: A systematic review and meta-analysis [0.03%]
肝细胞癌质子束治疗的近期更新：系统回顾和meta分析
Sun Hyun Bae,Won Il Jang,Hanna Rahbek Mortensen et al.
Sun Hyun Bae et al.
Backgrounds/aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore, we ...
Assessment of Real-Time US-CT/MR-guided Percutaneous Gold Fiducial Marker Implementation in Malignant Hepatic Tumors for Stereotactic Body Radiation Therapy [0.03%]
实时超声/CT/MR引导经皮金标记定位种子在恶性肝脏肿瘤立体定向体部放射治疗中的应用评价
Sungjun Hwang,Seok-Joo Chun,Eui Kyu Chie et al.
Sungjun Hwang et al.
Background/aims: This study explored the initial institutional experience of using gold fiducial markers for stereotactic body radiotherapy (SBRT) in treating malignant hepatic tumors using real-time ultrasound-computed t...
Heavy Smoking Increases Early Mortality Risk in Patients with Hepatocellular Carcinoma after Curative Treatment [0.03%]
吸烟对肝癌根治术后生存影响的量化研究
Jaejun Lee,Jong Young Choi,Soon Kyu Lee
Jaejun Lee
Background: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking on ...
Cure can be Achieved by Conversion to Microwave Ablation following Atezolizumab-Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma [0.03%]
阿特朱单抗联合贝伐珠单抗治疗后转为微波消融可使不可切除的肝细胞癌获得治愈性疗效
Rene John D Febro,Engelbert Simon S Perillo,Akemi A Kimura et al.
Rene John D Febro et al.
Introduction: Atezolizumab/bevacizumab is the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) and may facilitate curative conversion through resection and locoregional therapies. H...